Healthcare Sales & Marketing Network News: gemcitabine

Searching News Database: gemcitabine

HSMN NewsFeed - 18 Feb 2025
Oncolytics Biotech(R) Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 Jan 2025
New Drug Application Initiated with U.S. FDA for TAR-200, the First and Only Intravesical Drug Releasing System for Patients with BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer
Biopharmaceuticals Drug Delivery Oncology FDA

HSMN NewsFeed - 9 Jun 2023
Astellas Submits New Drug Application for Zolbetuximab in Japan
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 7 Sep 2021
RenovoRx Receives New 510(k) Clearance for its RenovoCath(R) Delivery System Designed for Targeted Treatment of Solid Tumors
Devices Drug Delivery Oncology FDA

HSMN NewsFeed - 26 Mar 2021
European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 18 Aug 2020
Innovent and Lilly Announce Expansion of TYVYT(R) (Sintilimab Injection) Licensing Agreement
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 12 Aug 2020
Innovent and Eli Lilly Announce Acceptance of a Supplemental New Drug Application of TYVYT(R) (Sintilimab Injection) in Combination with Gemcitabine and Platinum as First-Line Therapy in Squamous Non-Small Cell Lung Cancer in China
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 9 Apr 2020
EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO(R) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 13 Feb 2020
Decipher GRID Signature Predicts Benefit from Chemotherapy in Men Diagnosed with Metastatic Prostate Cancer
Diagnostics Oncology

HSMN NewsFeed - 20 Jan 2020
Armas Pharmaceuticals Adds Four Generic Injectables As First Launches of 2020
Biopharmaceuticals Generics Product Launch

HSMN NewsFeed - 4 Feb 2019
BioLineRx Receives Orphan Drug Designation From the FDA for its Lead Therapeutic Candidate BL-8040 for the Treatment of Pancreatic Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 18 Jan 2019
Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO(R)
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Jan 2019
Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Nov 2018
Senhwa Biosciences Silmitasertib filed IND of Basal Cell Carcinoma approved by FDA
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 22 Aug 2018
Sierra Oncology Obtains Debt Facility from Silicon Valley Bank to Acquire and Advance Momelotinib
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 22 Aug 2018
Sierra Oncology Acquires Momelotinib, an Investigational Janus Kinase (JAK) 1/2 and Activin Receptor Type 1 (ACVR1) Inhibitor for Myelofibrosis, from Gilead Sciences
Biopharmaceuticals Oncology Acquisitions

HSMN NewsFeed - 9 Jul 2018
Results of Phase III (PIX306) Trial Evaluating Progression-Free Survival of PIXUVRI(R) (pixantrone) Combined with Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jul 2018
MabVax Therapeutics Grants Exclusive Sublicense to Y-mAbs Therapeutics for Patented Neuroblastoma Vaccine
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 22 Jun 2018
PharmaEngine Announces Positive Topline Results from Global Pivotal Trial of PEP503 (NBTXR3) in Soft Tissue Sarcoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Jun 2018
Caris Life Sciences Presents Data Demonstrating the Ability of ADAPT Biotargeting System to Identify Responders and Non-Responders in a Phase III Pancreatic Cancer Study
Diagnostics Oncology

HSMN NewsFeed - 5 Jun 2018
FDA Expands Lilly's ALIMTA(R) (pemetrexed) Label to Include Combination with KEYTRUDA(R) (pembrolizumab) and Carboplatin as First-Line Treatment for Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective of PD-L1 Expression
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 5 Feb 2018
Tessa Therapeutics Announces Opening of Recruitment Sites Across the United States for its Phase III Nasopharyngeal Cancer Immunotherapy Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Jan 2018
MabVax Therapeutics Holdings, Inc. Provides Business Strategy Update
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Nov 2017
Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 29 Aug 2017
ARMO BioSciences Raises $67 Million in a Series C-1 Financing
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 19 Apr 2017
CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue Sarcomas
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 9 Jan 2017
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
Biopharmaceuticals Oncology Acquisitions

HSMN NewsFeed - 14 Nov 2016
Boston Biomedical Announces Orphan Drug Designation for Napabucasin in Pancreatic Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 18 Oct 2016
Shire Granted EU Marketing Authorization of Onivyde(R), in Combination With 5-Fluorouracil (5-FU) and Leucovorin (LV),for the Treatment of Metastatic Adenocarcinoma of the Pancreas in Adult Patients Who Have Progressed Following Gemcitabine-Based Therapy
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 11 Oct 2016
New European Society of Medical Oncology (ESMO) Biliary Cancer Guidelines Indicate Selective Internal Radiation Therapy (SIRT) with Y-90 Microspheres as an Option for Post-Chemotherapy Treatment of Intrahepatic Cholangiocarcinoma (iCCA)
Devices Oncology

HSMN NewsFeed - 29 Aug 2016
Leap Therapeutics and Macrocure Announce Definitive Merger Agreement
Biopharmaceuticals Wound Care Mergers & Acquisitions

HSMN NewsFeed - 25 Jul 2016
ONIVYDE(R) Receives Positive CHMP Opinion for Treatment of Patients with Metastatic Adenocarcinoma of the Pancreas Who Have Progressed Following Gemcitabine Based Therapy
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 16 Jun 2016
Merck’s KEYTRUDA(R) (pembrolizumab) Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 Mar 2016
Merrimack Announces Inclusion of ONIVYDE(R) (irinotecan liposome injection) as a Category 1 Treatment Option in the 2016 NCCN Guidelines for Pancreatic Adenocarcinoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Mar 2016
Allergan Confirms Generic Abraxane(R) Patent Challenge
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 25 Jan 2016
Boston Biomedical's Investigational Cancer Stem Cell Pathway Inhibitor, Napabucasin (BBI608), Featured at the ASCO 2016 Gastrointestinal Cancers Symposium
Biopharmaceuticals Oncology Gastroenterology

HSMN NewsFeed - 22 Oct 2015
Merrimack Announces U.S. FDA Approval of ONIVYDE(TM) (irinotecan liposome injection) for the Treatment of Patients with Metastatic Pancreatic Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 6 Aug 2015
Merrimack Pharmaceuticals Names Dr. Yasir Al-Wakeel as Chief Financial Officer and Head of Corporate Development
Biopharmaceuticals Drug Delivery Oncology Personnel

HSMN NewsFeed - 12 May 2015
Merck KGaA, Darmstadt, Germany, Receives FDA Fast Track Designation for Evofosfamide for the Treatment of Patients Living With Advanced Pancreatic Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 18 Mar 2015
Hong Kong Authority Approves Abraxane(R) as First-Line Treatment For Late-Stage Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 20 Jan 2015
CytRx Announces FDA's Removal of Partial Clinical Hold for Aldoxorubicin Clinical Trials Permitting Immediate Enrollment of New Patients
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 6 Jan 2015
CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results in Glioblastoma Multiforme (Brain Cancer)
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Dec 2014
CytRx Receives Written FDA Communication Regarding Partial Clinical Hold for Aldoxorubicin Clinical Trials
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Nov 2014
FDA Grants Orphan Drug Designation to Merrimack Pharmaceuticals' MM-141 for the Treatment of Pancreatic Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 Sep 2014
CTI BioPharma And Servier Announce Exclusive License And Collaboration Agreement To Develop And Commercialize PIXUVRI(R)
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 25 Jul 2014
Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR(R) (sorafenib) in Patients with Advanced Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 May 2014
Merrimack Pharmaceuticals Announces MM-398 Achieves Primary Endpoint of Overall Survival in Phase 3 Trial in Post-Gemcitabine Metastatic Pancreatic Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Mar 2014
Bayer and Onyx Report Phase 3 Study Results of NEXAVAR(R) (sorafenib) as Adjuvant Treatment for Patients with Liver Cancer Who Have Undergone Surgery or Local Ablation
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 Jan 2014
Novocure Enrolls First Patient in Pilot Clinical Trial of NovoTTF(TM) Therapy Plus Gemcitabine for First-line Treatment of Advanced Pancreatic Adenocarcinoma
Devices Oncology

HSMN NewsFeed - 6 Jan 2014
PIXUVRI(R) (pixantrone) Receives Positive Final Appraisal Determination from NICE
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 12 Dec 2013
Senhwa Biosciences Raises $17M Series B
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 4 Dec 2013
Cell Therapeutics and GKV-SV Reach Agreement on Pricing of PIXUVRI(R) (pixantrone) in Germany
Biopharmaceuticals Oncology Reimbursement

HSMN NewsFeed - 22 Nov 2013
Threshold Pharmaceuticals Announces New Clinical Data on TH-302 and Avastin(R) (Bevacizumab) in Recurrent Glioblastoma Following Bevacizumab Failure
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Oct 2013
Lorus Therapeutics Appoints New Chief Executive Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 15 Oct 2013
Second Draft NICE Guidance for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 6 Sep 2013
U.S. Food and Drug Administration Approves ABRAXANE(R) in Combination with Gemcitabine as First-Line Treatment of Patients with Metastatic Pancreatic Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 19 Aug 2013
Market Access Granted in France for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 8 Jul 2013
Market Access Granted in Italy for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 8 Jul 2013
Cell Therapeutics Provides Reimbursement Update for the UK for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Biopharmaceuticals Oncology Reimbursement

HSMN NewsFeed - 15 May 2013
Bayer Initiates Phase III Trial of Stivarga(R) (regorafenib) Tablets in Patients with Advanced Liver Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jan 2013
Phase 3 DECISION Trial of Nexavar(R) (sorafenib) Meets Primary Endpoint of Improving Progression-Free Survival in Patients with Radioactive Iodine Refractory Differentiated Thyroid Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Nov 2012
Clovis Oncology Announces Negative Outcome of CO-101 in Pivotal LEAP Pancreatic Cancer Study
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Sep 2012
Cell Therapeutics Announces European Launch Of Pixuvri(R) For Treatment Of Adult Patients With Multiply Relapsed Or Refractory Aggressive Non-Hodgkin B-Cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 Jul 2012
Addition of Tarceva(R) (erlotinib) to Nexavar(R) (sorafenib) did not Provide Additional Benefit to Patients with Unresectable Liver Cancer Versus Nexavar alone in Phase 3 Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Jun 2012
Cell Therapeutics Appoints New Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 31 May 2012
Cell Therapeutics' Pixuvri(R) Phase 3 Clinical Trial Results Published in The Lancet Oncology
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Feb 2012
Threshold Pharmaceuticals and Merck KGaA Announce Global Agreement to Co-Develop and Commercialize Phase 3 Hypoxia-Targeted Drug TH-302
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Nov 2011
Curis Announces Appointment of Maurizio Voi, M.D. as Chief Medical and Chief Development Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 24 Feb 2011
Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Feb 2011
Third Phase III Study of Avastin-Based Regimen Met Primary Endpoint in Ovarian Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Feb 2011
Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Jan 2011
APP Pharmaceuticals Announces Agreement with Teva Pharmaceuticals to Manufacture and Market Gemcitabine HCI for Injection
Biopharmaceuticals Licensing Oncology

HSMN NewsFeed - 19 Jan 2011
Precision Therapeutics Announces Two Pancreatic Cancer Studies Emphasizing the Utility of ChemoFx(R) in Cancer Treatment Options
Diagnostics Personalized Medicine Oncology

HSMN NewsFeed - 5 Jan 2011
TetraLogic Closes $23 Million Second Tranche of Series C Financing
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 29 Jul 2010
US Appeals Court Rules Gemzar(R) Patent Invalid
Biopharmaceuticals Generics Oncology Litigation

HSMN NewsFeed - 30 Jun 2010
Celgene to Acquire Abraxis BioScience Inc.
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 14 Jun 2010
Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Jun 2010
Immunomedics Reports Updated Results of Targeted Therapy for Advanced Pancreatic Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Apr 2010
OSI Pharmaceuticals Announces That Tarceva(R) Received Approval in the European Union for Maintenance Use in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 19 Mar 2010
OSI Pharmaceuticals Announces That Tarceva(R) Received a Positive Opinion from Health Authorities in the European Union for First-Line Maintenance Use in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 9 Feb 2010
BSD Medical Reports Initiation of a Phase III Study on Pancreatic Cancer Using the BSD-2000 Hyperthermia System in Combination with Chemotherapy
Devices Oncology

HSMN NewsFeed - 19 Jan 2010
GlobeImmune Announces $17.5 Million Series E Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 15 Jan 2010
FDA Extends Review Period for Tarceva Application for First-Line Maintenance Use in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Nov 2009
OSI Pharmaceuticals Announces Tarceva to Be Reviewed by the FDA's Oncologic Drugs Advisory Committee for Use as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 5 Nov 2009
ABRAXANE(R) Receives Orphan Drug Status for the Treatment of Pancreatic Cancer and Stage IIB-IV Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 15 Oct 2009
Threshold Pharmaceuticals Licenses Glufosfamide to Eleison Pharmaceuticals
Biopharmaceuticals Licensing

HSMN NewsFeed - 30 Sep 2009
Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Aug 2009
Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival (PFS) in Women with Previously Treated Advanced Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Aug 2009
New Data from Phase III SATURN Study Showed Tarceva Extended Survival in Patients with Advanced Non-Small Cell Lung Cancer When Used Immediately after Initial Chemotherapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 Jul 2009
Eli Lilly & Company and ScinoPharm Taiwan Ltd. Announce Settlement of Gemcitabine Litigation
Biopharmaceuticals Litigation Licensing

HSMN NewsFeed - 22 Jul 2009
Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 13 Jul 2009
New Data from Phase III SATURN Study Showed Tarceva Improved Overall Survival When Used Immediately After Initial Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 Apr 2009
Roche Announces Collaboration to Investigate New Treatment Strategy With Tarceva in Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Mar 2009
OSI Pharmaceuticals Submits Supplemental New Drug Application to the FDA for Tarceva as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 5 Feb 2009
Immunomedics' hPAM4 Labeled With Yttrium-90 Receives Fast Track Designation From FDA for Therapy of Pancreatic Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 7 Jan 2009
Marshall Edwards, Inc. Granted IND for Triphendiol
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 26 Nov 2008
Tarceva(R) (erlotinib) Endorsed by the U.K.'s National Institute for Health and Clinical Excellence for Use in Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Oct 2008
Pfizer Names New Head of Clinical Development and Medical Affairs for Its Oncology Business Unit
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 6 Oct 2008
Lilly to Acquire ImClone Systems in $6.5 Billion Transaction
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 29 Sep 2008
FDA Grants Lilly's ALIMTA(R) (Pemetrexed for Injection) Third U.S. Approval
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 10 Sep 2008
AmpliMed Announces License Agreement with Handok Pharmaceuticals for Exclusive Rights to Cancer Therapeutic Amplimexon(R) in Korea
Biopharmaceuticals Licensing

HSMN NewsFeed - 14 Jul 2008
Immunomedics Announces Worldwide License and Collaboration Agreement With Nycomed for Veltuzumab for Non-Cancer Indications
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 7 Jul 2008
Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2008
MethylGene Reports Clinical Data for MGCD0103 at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2008
Patients With Pancreatic Cancer can Benefit From Avastin(R) Plus Tarceva(R)
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2008
Amgen Presents New Data at ASCO on Four Investigational Molecules from Oncology Pipeline
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2008
New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 May 2008
Study Showed ALIMTA(R) (pemetrexed for injection) Improved Survival in Certain Types of Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 May 2008
Cyclacel's Sapacitabine Receives Orphan Designation for AML & MDS From EU Regulators
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 15 May 2008
ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection)
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 Apr 2008
Multiple Studies Demonstrate the Use of Hyperthermia Therapy in Treating Pancreatic Cancer
Devices Oncology

HSMN NewsFeed - 23 Apr 2008
Abraxis BioScience Reports Promising Clinical Data in Advanced Pancreatic Cancer Using a Combination of nab-Paclitaxel (ABRAXANE(R)) and Gemcitabine (Gemzar(R))
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Apr 2008
Genentech Provides Update on ''AVAiL'' Phase III Study of Avastin Plus Chemotherapy in First-Line, Advanced, Non-Squamous, Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Apr 2008
European Regulatory Agency Grants Orphan Status to Morphotek(R)'s Farletuzumab and MORAb-009
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 11 Apr 2008
ALIMTA(R) (pemetrexed for injection) Receives European Approval for Histologically-Based Use in First-Line Treatment of Most Common Lung Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 2 Apr 2008
European Regulatory Agency Accepts Cell Therapeutics, Inc.'s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 4 Mar 2008
Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 18 Feb 2008
Bayer and Onyx Provide Update on Phase 3 Trial of Nexavar in Patients With Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Dec 2007
Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 14 Dec 2007
OSI Pharmaceuticals Announces Launch Date of Tarceva(R) (erlotinib) in Japan
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 29 Oct 2007
Threshold Pharmaceuticals Announces Corporate Realignment
Biopharmaceuticals

HSMN NewsFeed - 25 Oct 2007
Jeffrey D. Bloss, M.D., Joins Xencor as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 22 Oct 2007
Tarceva(R) (erlotinib) Earns Approval for Lung Cancer Patients in Japan
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 26 Sep 2007
GlobeImmune Raises $41.2 Million in Series C Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 20 Sep 2007
Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 18 Sep 2007
OSI Pharmaceuticals Announces Patent Term Extension for Tarceva(R) (erlotinib)
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Sep 2007
OSI Pharmaceuticals Summarizes Data Presented on Tarceva(R) (erlotinib) at the 12th World Congress on Lung Cancer Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Sep 2007
Roche's Tarceva(R) Delivers Longer Life for Lung Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 Aug 2007
A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 Jul 2007
Cell Therapeutics, Inc. (CTI) Announces Agreement to Acquire SMi; Gains Global Rights to Brostallicin, in a New Class of Cancer Killing Agents
Biopharmaceuticals Mergers & Acquisitions Oncology

HSMN NewsFeed - 12 Jul 2007
Point Therapeutics Update
Biopharmaceuticals

HSMN NewsFeed - 20 Jun 2007
NCCN Updates Non-Hodgkin's Lymphoma Guidelines
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Jun 2007
Extensive Clinical Data on ERBITUX(R) Presented at the 2007 ASCO Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Jun 2007
OSI Pharmaceuticals Summarizes Data on Tarceva(R) (erlotinib) at the 2007 American Society of Clinical Oncology (ASCO) Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Jun 2007
XYOTAX(TM) More Cost Effective With Fewer Side Effects Than Gemcitabine or Vinorelbine in Treating Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Jun 2007
New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
New Data Show Pfizer's Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
Genentech Provides Update on Pipeline Agents at the American Society of Clinical Oncology Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
Study Presented at ASCO Shows Encouraging One-Year and Overall Survival Results for Phase I/II Trial of OGX-011 in Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2007
Clinical Data Suggest Potential Versatility of ALIMTA(R) (Pemetrexed for Injection)-Based Regimens in Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2007
Study Supports Activity of GEMZAR(R) (Gemcitabine HC1 for Injection) in the Treatment of Early-Stage Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2007
Second Phase III Study of Avastin Plus Chemotherapy Shows Improved Progression-Free Survival in First-Line Non-Squamous, Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2007
Point Therapeutics Reduces Costs by Cutting Work Force
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 May 2007
New Data Highlighting ABRAXANE as Single Agent and in Combination for the Treatment of Breast, Lung and Ovarian Cancers to Be Presented at ASCO
Biopharmaceuticals Drug Delivery Oncology

HSMN NewsFeed - 21 May 2007
Talabostat Clinical Program Put on Clinical Hold by FDA
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 May 2007
Point Therapeutics Announces Interim Analysis to be Performed on Its Phase 3 Talabostat with Alimta Study
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 May 2007
Teva Announces Tentative Approval of Generic Gemzar(R) for Injection
Biopharmaceuticals Generics Oncology FDA

HSMN NewsFeed - 30 Apr 2007
Cyclacel Pharmaceuticals Begins Phase II Study of Oral Sapacitabine in Patients with Advanced Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Apr 2007
SciClone Acquires Clinical-Stage Pancreatic Cancer Compound
Biopharmaceuticals Oncology Acquisitions

HSMN NewsFeed - 26 Apr 2007
Avantogen Oncology, Inc. Completes Major Transaction With SciClone Pharmaceuticals, Inc.
Biopharmaceuticals Oncology Acquisitions

HSMN NewsFeed - 25 Apr 2007
OSI Pharmaceuticals Announces Pivotal Phase III Tarceva(R) Study Published in the Journal of Clinical Oncology Showed Survival Improvement in Patients with Pancreatic Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Apr 2007
Cyclacel Pharmaceuticals Reports Preclinical Seliciclib-Erlotinib Synergy Data at AACR
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 Apr 2007
Lilly Oncology Focused on Pharmacogenomics at AACR Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Apr 2007
Data Available from ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Apr 2007
Coley Pharmaceutical Group Announces Completion of Patient Enrollment in Pfizer's Two Pivotal Phase III NSCLC Clinical Trials
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Mar 2007
Point Therapeutics Provides Clinical Update
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Feb 2007
Threshold Pharmaceuticals Announces That a Phase 3 Clinical Trial of Glufosfamide for Treatment of Pancreatic Cancer Did Not Meet Its Primary Endpoint
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Feb 2007
Analysis of International Phase III Study of Avastin(R) Plus Chemotherapy Shows Improved Progression-Free Survival in Patients With Advanced Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Jan 2007
OSI Pharmaceuticals Announces European Regulatory Approval of Tarceva(R) for Treatment of Patients with Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 24 Jan 2007
Point Therapeutics Announces Resignation of William Whelan from Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 22 Jan 2007
Cell Genesys Announces Encouraging Follow-Up Survival Data From Phase 2 Clinical Trial of GVAX(R) Immunotherapy for Pancreatic Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Jan 2007
Point Therapeutics Provides Preliminary Results from Phase 2 Metastatic Pancreatic Cancer Study
Biopharmaceuticals

HSMN NewsFeed - 8 Jan 2007
Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2007 Goals at JPMorgan Healthcare Conference
Biopharmaceuticals

HSMN NewsFeed - 2 Jan 2007
Phase II clinical trial of Biomira's PX-12 in patients with advanced pancreatic cancer now open for patient enrollment
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 Dec 2006
OSI Pharmaceuticals Announces That Tarceva(R) Received Positive Opinion from Health Authorities in European Union for the Treatment of Patients with Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 11 Dec 2006
Abraxis BioScience to Present Data from Six Studies at San Antonio Breast Cancer Symposium
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Nov 2006
Threshold Pharmaceuticals Announces Change in Guidance for Release of Phase 3 Trial Results in Pancreatic Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 Oct 2006
Biomira Announces Acquisition of ProlX Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 30 Oct 2006
Avantogen Oncology Inc. Announces FDA Acceptance Of Its IND For The Novel Cancer Drug Candidate, RP101
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 23 Oct 2006
Threshold Pharmaceuticals Announces Management Update
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Oct 2006
Human Genome Sciences Reports Significant Progress and Outlines Its Next Steps on the Path to Commercialization
Biopharmaceuticals

HSMN NewsFeed - 2 Oct 2006
Avantogen Oncology Inc. Files IND Application for RP101
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 2 Oct 2006
Patients With HER2-Positive Breast Cancer Significantly Benefit From Addition of Xeloda to Herceptin and Taxotere Therapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Sep 2006
OSI Pharmaceuticals Launches Study of Tarceva(R) as Adjuvant Treatment for Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Sep 2006
Threshold Pharmaceuticals Announces Management Update
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 19 Jul 2006
BSD Medical's BSD-2000 May Provide Hope for Pancreatic Cancer Patients
Devices Oncology

HSMN NewsFeed - 17 Jul 2006
FDA Approves Lilly's Gemzar(R) For Ovarian Cancer Treatment
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 27 Jun 2006
Phase III Study of Avastin(R) in Advanced Pancreatic Cancer Does Not Meet Primary Endpoint
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Jun 2006
Threshold Announces Data Safety Monitoring Board Recommends Glufosfamide Phase 3 Clinical Trial Continue to Completion
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Jun 2006
Point Therapeutics Receives Fast Track Designation for Talabostat
Biopharmaceuticals Oncology FDA

Return to NewsFeed

Additional items found! 137

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 137 additional stories matching:
gemcitabine
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.